Latest Options News

Nova Minerals has sent out its Scheme Booklet to shareholders and warrantholders, setting the stage for a May 29 vote on its proposed move from Australia to the US. The Independent Expert backs the scheme, and directors recommend approval.

Lake Resources made solid progress on the Exploitation Environmental Impact Assessment for its Kachi Lithium Brine Project, targeting approval in Q3 2026, while maintaining strong liquidity and strategic partnerships.

IRIS Metals has revealed a 3.03Mt lithium resource at its fully permitted Beecher Project in South Dakota, featuring a notable rubidium component with a high-grade zone containing around 2,100 tonnes of Rb2O. This positions Beecher as a rare multi-commodity critical minerals asset in a top US mining jurisdiction.

First Au Limited has boosted confidence in its Gimlet Gold Project by upgrading 62% of its resource to Indicated, while streamlining its focus on Western Australian gold through the acquisition of the Barlee Project and exiting offshore assets.

Xamble Group stabilised revenue at A$1.64 million in Q1 2026 while narrowing its group EBITDA loss slightly despite ramped-up technology spending. The company completed its acquisition of YouthsToday, tripling its influencer base and locking in three commercial contracts worth A$1.17 million.

PhosCo Ltd advances its Gasaat Phosphate Project with robust drilling results at KM and SAB deposits, confirming thick, high-grade mineralisation. Imminent maiden resource estimates and a significant new discovery at DOH underscore the project's growing global significance amid supply chain disruptions.

Skylark Minerals has kicked off its largest drilling campaign at the Zaranou Gold Project in Côte d’Ivoire, confirming deeper and thicker gold mineralisation that could expand its 364,600-ounce inferred resource.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Central Petroleum lifted March quarter sales revenue to $11.3 million, driven by higher gas volumes and prices, while securing a significant multi-year gas supply deal with the Northern Territory Government that supports a 40% production capacity increase at Palm Valley.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Mammoth Minerals reported significant shallow gold intercepts at its Excelsior Springs project in Nevada, expanded its landholding with the Imperial Gold Project acquisition, and completed the Paterson divestment, positioning itself for further exploration growth.